Complement 3d: from molecular adjuvant to target of immune escape mechanisms.

[1]  N. Greenspan,et al.  Genetic fusion of three tandem copies of murine C3d sequences to diphtheria toxin fragment B elicits a decreased fragment B-specific antibody response. , 2006, Immunology letters.

[2]  H. D. del Portillo,et al.  Clinical and molecular aspects of severe malaria. , 2005, Anais da Academia Brasileira de Ciencias.

[3]  A. Trkola,et al.  Complement dependent trapping of infectious HIV in human lymphoid tissues , 2005, AIDS.

[4]  E. Bergmann-Leitner,et al.  C3d binding to the circumsporozoite protein carboxy-terminus deviates immunity against malaria. , 2005, International immunology.

[5]  A. Strongin,et al.  Cellular Membrane Type-1 Matrix Metalloproteinase (MT1-MMP) Cleaves C3b, an Essential Component of the Complement System* , 2004, Journal of Biological Chemistry.

[6]  M. Dierich,et al.  Cutting Edge: Productive HIV-1 Infection of Dendritic Cells via Complement Receptor Type 3 (CR3, CD11b/CD18) , 2004, The Journal of Immunology.

[7]  M. Netea,et al.  Recognition of fungal pathogens by Toll-like receptors , 2004, European Journal of Clinical Microbiology and Infectious Diseases.

[8]  D. Karp,et al.  Cutting Edge: C3d Functions as a Molecular Adjuvant in the Absence of CD21/35 Expression 1 , 2004, The Journal of Immunology.

[9]  J. Sodroski,et al.  Elicitation of Neutralizing Antibodies with DNA Vaccines Expressing Soluble Stabilized Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Trimers Conjugated to C3d , 2004, Journal of Virology.

[10]  P. Jahrling,et al.  Smallpox DNA Vaccine Protects Nonhuman Primates against Lethal Monkeypox , 2004, Journal of Virology.

[11]  Lingshu Wang,et al.  Fusion to C3d Enhances the Immunogenicity of the E2 Glycoprotein of Type 2 Bovine Viral Diarrhea Virus , 2004, Journal of Virology.

[12]  Yueh J. Chang,et al.  Blocking Immune Evasion as a Novel Approach for Prevention and Treatment of Herpes Simplex Virus Infection , 2003, Journal of Virology.

[13]  E. Bergmann-Leitner,et al.  Identification and targeting of tumor escape mechanisms: a new hope for cancer therapy? , 2003, Current pharmaceutical design.

[14]  Anna Erdei,et al.  Regulation of B-cell activation by complement receptors CD21 and CD35. , 2003, Current pharmaceutical design.

[15]  M. Dierich,et al.  Mechanism(s) promoting HIV‐1 infection of primary unstimulated T lymphocytes in autologous B cell/T cell co‐cultures , 2003, European journal of immunology.

[16]  T. Leanderson,et al.  Was It There All the Time? , 2003, Scandinavian journal of immunology.

[17]  A. Blom,et al.  Functional Activity of the Complement Regulator Encoded by Kaposi's Sarcoma-associated Herpesvirus* , 2003, The Journal of Biological Chemistry.

[18]  T. Ross,et al.  Induction of heterosubtypic immunity to influenza A virus using a DNA vaccine expressing hemagglutinin-C3d fusion proteins. , 2003, Vaccine.

[19]  D. Montefiori,et al.  Enhancement of Antibodies to the Human Immunodeficiency Virus Type 1 Envelope by Using the Molecular Adjuvant C3d , 2003, Journal of Virology.

[20]  H. Kaplan,et al.  Tolerance is dependent on complement C3 fragment iC3b binding to antigen-presenting cells , 2003, Nature Medicine.

[21]  A. Sher,et al.  Evasion of innate immunity by parasitic protozoa , 2002, Nature Immunology.

[22]  R. Weiss,et al.  Gene gun bombardment with gold particles displays a particular Th2-promoting signal that over-rules the Th1-inducing effect of immunostimulatory CpG motifs in DNA vaccines. , 2002, Vaccine.

[23]  K. Matsunami,et al.  Regulation of complement-mediated swine endothelial cell lysis by herpes simplex virus glycoprotein, gC1. , 2002, Journal of biochemistry.

[24]  J. Prechl,et al.  Complement Receptor Type 1 (CD35) Mediates Inhibitory Signals in Human B Lymphocytes1 , 2002, The Journal of Immunology.

[25]  A. Frey,et al.  A tumor-expressed inhibitor of the early but not late complement lytic pathway enhances tumor growth in a rat model of human breast cancer. , 2002, Cancer research.

[26]  M. Zabel,et al.  Depletion of Lyn kinase from the BCR complex and inhibition of B cell activation by excess CD21 ligation. , 2002, International immunology.

[27]  S. Norris,et al.  Mycobacterial Protein HbhA Binds Human Complement Component C3 , 2001, Infection and Immunity.

[28]  L. Babiuk,et al.  Fusion of C3d molecule with bovine rotavirus VP7 or bovine herpesvirus type 1 glycoprotein D inhibits immune responses following DNA immunization. , 2001, Veterinary immunology and immunopathology.

[29]  P. Rota,et al.  C3d enhancement of neutralizing antibodies to measles hemagglutinin. , 2001, Vaccine.

[30]  R. Sinden,et al.  Interaction between Host Complement and Mosquito-Midgut-Stage Plasmodium berghei , 2001, Infection and Immunity.

[31]  Ziya Kaya,et al.  Contribution of the innate immune system to autoimmune myocarditis: a role for complement , 2001, Nature Immunology.

[32]  S. Pierce,et al.  The Role of the CD19/CD21 Complex in B Cell Processing and Presentation of Complement-Tagged Antigens , 2001, The Journal of Immunology.

[33]  D. Montefiori,et al.  Enhanced avidity maturation of antibody to human immunodeficiency virus envelope: DNA vaccination with gp120-C3d fusion proteins. , 2001, AIDS research and human retroviruses.

[34]  P. Arese,et al.  Growth of Plasmodium falciparum induces stage‐dependent haemichrome formation, oxidative aggregation of band 3, membrane deposition of complement and antibodies, and phagocytosis of parasitized erythrocytes , 2001, British journal of haematology.

[35]  A. Lucas,et al.  Increased Immunogenicity and Induction of Class Switching by Conjugation of Complement C3d to Pneumococcal Serotype 14 Capsular Polysaccharide , 2001, Infection and Immunity.

[36]  T. Ross,et al.  C3d enhancement of antibodies to hemagglutinin accelerates protection against influenza virus challenge , 2000, Nature Immunology.

[37]  S. Meri,et al.  Exceptional Resistance of Human H2 Glioblastoma Cells to Complement-Mediated Killing by Expression and Utilization of Factor H and Factor H-Like Protein 11 , 2000, The Journal of Immunology.

[38]  C. Nielsen,et al.  The role of complement in the acquired immune response , 2000, Immunology.

[39]  G. Kelsoe,et al.  Humoral Immune Responses in Cr2−/− Mice: Enhanced Affinity Maturation but Impaired Antibody Persistence1 , 2000, The Journal of Immunology.

[40]  G. Tsokos,et al.  Enhanced and sustained activation of human B cells by anti‐immunoglobulin conjugated to the EBV glycoprotein gp350 , 2000, European journal of immunology.

[41]  R. Frade.  Structure and functions of proteases which cleave human C3 and are expressed on normal or tumor human cells: some are involved in tumorigenic and metastatic properties of human melanoma cells. , 1999, Immunopharmacology.

[42]  Stephen Tomlinson,et al.  Characterization of a Novel Trypanosome Lytic Factor from Human Serum , 1999, Infection and Immunity.

[43]  D. L. Griffith,et al.  Two Functional States of the CD11b A-Domain: Correlations with Key Features of Two Mn2+-complexed Crystal Structures , 1998, The Journal of cell biology.

[44]  A. Stringaro.  Expression of the complement-binding protein (MP60) of Candida albicans in experimental vaginitis , 1998, Mycopathologia.

[45]  M. Carroll,et al.  Evidence for an important interaction between a complement-derived CD21 ligand on follicular dendritic cells and CD21 on B cells in the initiation of IgG responses. , 1998, Journal of immunology.

[46]  F. Vivanco,et al.  A small domain (6.5 kDa) of bacterial protein G inhibits C3 covalent binding to the Fc region of IgG immune complexes , 1998, European journal of immunology.

[47]  G. Tsokos,et al.  Complement receptor 2 in the regulation of the immune response. , 1998, Clinical immunology and immunopathology.

[48]  S. Varsano,et al.  Human lung cancer cell lines express cell membrane complement inhibitory proteins and are extremely resistant to complement‐mediated lysis; a comparison with normal human respiratory epithelium in vitro, and an insight into mechanism(s) of resistance , 1998, Clinical and experimental immunology.

[49]  D. Gray,et al.  T Cell–dependent Immune Response in C1q-deficient Mice: Defective Interferon γ Production by Antigen-specific T Cells , 1998, The Journal of experimental medicine.

[50]  John D Lambris,et al.  Interaction of vaccinia virus complement control protein with human complement proteins: factor I-mediated degradation of C3b to iC3b1 inactivates the alternative complement pathway. , 1998, Journal of immunology.

[51]  W. Chaffin,et al.  Cell Wall and Secreted Proteins ofCandida albicans: Identification, Function, and Expression , 1998, Microbiology and Molecular Biology Reviews.

[52]  V. Holers,et al.  Cross-linking CD21/CD35 or CD19 increases both B7-1 and B7-2 expression on murine splenic B cells. , 1998, Journal of immunology.

[53]  W. Ballou,et al.  Immune responses induced by intramuscular or gene gun injection of protective deoxyribonucleic acid vaccines that express the circumsporozoite protein from Plasmodium berghei malaria parasites. , 1997, Journal of immunology.

[54]  J. Inman,et al.  The affinity threshold for human B cell activation via the antigen receptor complex is reduced upon co-ligation of the antigen receptor with CD21 (CR2). , 1997, Journal of immunology.

[55]  E. Brown,et al.  A macrophage invasion mechanism of pathogenic mycobacteria. , 1997, Science.

[56]  Yang,et al.  P. falciparum rosetting mediated by a parasite-variant erythrocyte membrane protein and complement-receptor 1 , 1997, Nature.

[57]  W. Balch,et al.  Membrane fusion: Bridging the gap by AAA ATPases , 1997, Nature.

[58]  B. Kelsall,et al.  Regulation of Interleukin-12 by Complement Receptor 3 Signaling , 1997, The Journal of experimental medicine.

[59]  Hans Hengartner,et al.  Antigen localisation regulates immune responses in a dose‐ and time‐dependent fashion: a geographical view of immune reactivity , 1997, Immunological reviews.

[60]  E. Kremmer,et al.  Regulation of the B cell response to T-dependent antigens by classical pathway complement. , 1996, Journal of immunology.

[61]  R. Karr,et al.  Markedly impaired humoral immune response in mice deficient in complement receptors 1 and 2. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[62]  J. Ahearn,et al.  Disruption of the Cr2 locus results in a reduction in B-1a cells and in an impaired B cell response to T-dependent antigen. , 1996, Immunity.

[63]  Christopher C. Goodnow,et al.  C3d of Complement as a Molecular Adjuvant: Bridging Innate and Acquired Immunity , 1996, Science.

[64]  B. Heyman,et al.  Antibodies to murine complement receptor 1 and 2 can inhibit the antibody response in vivo without inhibiting T helper cell induction. , 1995, Journal of immunology.

[65]  W. Chaffin,et al.  Comparative study of the C3d receptor and 58-kilodalton fibrinogen-binding mannoproteins of Candida albicans , 1995, Infection and immunity.

[66]  V. Vetvicka,et al.  Natural antibody and complement-mediated antigen processing and presentation by B lymphocytes. , 1994, Journal of immunology.

[67]  V. Koistinen,et al.  Herpes simplex virus glycoprotein C: molecular mimicry of complement regulatory proteins by a viral protein. , 1993, Immunology.

[68]  J. Kwekkeboom,et al.  Direct evidence that human follicular dendritic cells (FDC) rescue germinal centre B cells from death by apoptosis , 1993, Clinical and experimental immunology.

[69]  R. Sinden,et al.  Plasmodium berghei: sporozoites are sensitive to human serum but not susceptible host serum. , 1992, Experimental parasitology.

[70]  D. Fearon,et al.  CD19: lowering the threshold for antigen receptor stimulation of B lymphocytes. , 1992, Science.

[71]  B. Bradt,et al.  Characterization of a Trypanosoma cruzi C3 binding protein with functional and genetic similarities to the human complement regulatory protein, decay-accelerating factor. , 1991, Journal of immunology.

[72]  K. Joiner,et al.  Serum resistance of metacyclic stage Leishmania major promastigotes is due to release of C5b-9. , 1990, Journal of immunology.

[73]  B. Moss,et al.  Inhibition of the complement cascade by the major secretory protein of vaccinia virus. , 1990, Science.

[74]  B. Heyman,et al.  In vivo inhibition of the antibody response by a complement receptor- specific monoclonal antibody , 1990, The Journal of experimental medicine.

[75]  F. Finkelman,et al.  Characterization of murine complement receptor type 2 and its immunological cross-reactivity with type 1 receptor. , 1990, International immunology.

[76]  John D Lambris,et al.  Monovalent ligands of complement receptor 2 inhibit whereas polyvalent ligands enhance anti-Ig-induced human B cell intracytoplasmic free calcium concentration. , 1990, Journal of immunology.

[77]  J. Diebold,et al.  Human follicular dendritic cells express CR1, CR2, and CR3 complement receptor antigens. , 1985, Journal of immunology.

[78]  N. Cooper,et al.  Complement activation by the surface of Plasmodium falciparum infected erythrocytes. , 1984, Molecular immunology.

[79]  H. Petty,et al.  Interactions of integrins with their partner proteins in leukocyte membranes , 2002, Immunologic research.

[80]  C. Janeway,et al.  Innate immune recognition. , 2002, Annual review of immunology.

[81]  D. Fearon,et al.  Regulation of B lymphocyte responses to foreign and self-antigens by the CD19/CD21 complex. , 2000, Annual review of immunology.

[82]  D. Russell,et al.  The interaction of Leishmania species with macrophages. , 1992, Advances in parasitology.